1. INTRODUCTION {#sec1}
===============

Antiepileptic drugs (AEDs) commonly act on diverse molecular targets to selectively attenuate the excitability of neurons and provide adequate seizure control in epileptic patients. There are multiple mechanisms of action of AEDs that can be categorized by their regulatory functions on voltage-gated ion channels and control of synaptic excitability \[[@r1]\]. However, current findings have shown that AEDs can exert their regulatory effects on gene expression as epigenetic modifiers, making them active in different studies of human medicine.

Epigenetics can be interpreted as heritable changes in gene function without alterations in the activity state of a DNA sequence \[[@r2]\]. Significant epigenetic markers include DNA methylation, modifications of histone proteins, and functions of untranslated RNAs. These epigenetic phenomena are usually followed by the identification of biomarkers that can translate molecular and genomic data into clinical practice, especially in oncology \[[@r3]\]. For example, aberrant expression levels of histone deacetylase (HDAC) 1, 2, and 3 are correlated with ovarian cancer and myeloma prognosis \[[@r4], [@r5]\]. Meanwhile, epigenetic modifiers targeting these biomarker proteins such as valproate acid (VPA) and tacedinaline, have been put into phase III clinical trials of ovarian cancer and myeloma therapy \[[@r6], [@r7]\]. Additionally, biomarker discovery can be regarded as an advance in the novel possibilities for the treatment of patients with epilepsy and psychological disorders \[[@r8], [@r9]\].

VPA, carbamazepine (CBZ), and other AEDs can exert epigenetic action in animal models and cells to develop potential drug targets for diseases. Through the genetic or pharmacologic targeting of DNA methyltransferase enzymes, specific gene loci can become hypomethylated, which may lead to the reactivation of silenced gene expression \[[@r10]\]. AEDs can also act as histone deacetylase inhibitors that induce different phenotypes in various transformed cells \[[@r11], [@r12]\]. Moreover, noncoding RNAs, such as microRNAs (miRNAs), can be modulated to silence chromatin, degrade mRNA, and block translation \[[@r13]\]. These drug effects have been widely used in various research fields.

Regarding the drugs themselves, adverse drug reactions (ADRs) and toxicity are associated with their epigenetic modifications \[[@r14], [@r15]\]. These epigenetic pathways can help researchers determine possible methods to predict and prevent adverse events and toxicity caused by AEDs.

In this review, we summarize recent data regarding the epigenetic effects mediated by AEDs with clinical implications in human diseases and pharmaceutical research. We searched PubMed and Web of Science for publications in English from Jan 1, 2010, to Apr 1, 2019. The search terms included "antiepileptic drugs","acetazolamide", "benzobarbital" "brivaracetam", "carbamazepine", "clonazepam", "diazepam", "cannabidiol", "felbamate", "gabapentin", "lacosamide", "lamotrigine", "levetiracetam", "lorazepam", "mephobarbital", "oxcarbazepine", "phenobarbital", "phenytoin", "primidone", "riluzole", "rufinamide", "tiagabine", "topiramate", "valproic acid", "zonisamide", "retigabine", "eslicarbazepine", "perampanel", "epigenetic effect\*", "DNA methylation", "histone modification", "untranslated RNA", "DNMT", "HDAC", "HAT", "HDACI", "MBD", "SAM", and "non-coding RNA". In addition, we also used the Mesh terms in Medline such as "DNA (Cytosine-5-)-Methyltransferases"\[Mesh\], "epigenomics"\[Mesh\], "S-Adenosylmethionine"\[Mesh\], "Methyl CpG Binding Domain"\[Mesh\], "epigenesis, genetic"\[Mesh\], "histone acetyltransferases"\[Mesh\], "histone deacetylases"\[Mesh\], "Histone Deacetylase Inhibitors"\[Mesh\], "rna, untranslated"\[Mesh\], "DNA methylation"\[Mesh\] OR "histone code"\[Mesh\], and "anticonvulsants"\[Pharmacological Action\]. Then, the pivotal clinical studies and experiment article were selected to describe our main topic. We also used some earlier reviews if they were principally relevant to the discussion.

2. THE EPIGENETIC EFFECTS OF ANTIEPILEPTIC DRUGS {#sec2}
================================================

2.1. DNA Methylation {#sec2.1}
--------------------

DNA methylation is perhaps the best characterized chemical modification of chromatin. In mammalian genes, most methylation processes occur on the cytosine residues of CpG dinucleotides \[[@r16]\]. *De novo* or maintenance DNA methyltransferases (DNMTs) play a significant role in gene regulation and chromatin organization during ontogenesis. DNMTs add methyl groups to hemimethylated DNA during or after DNA replication. Three active DNA methyltransferases have been identified in mammals, named DNMT1, DNMT3a, and DNMT3b \[[@r17]\]. In general, DNA methylation delivers a stable, inherited, and crucial constituent of epigenetic regulation \[[@r18]\].

However, this transient inherited change can be influenced by the environment, chemicals, cancer, and diseases \[[@r19]\]. Furthermore, drug exposure can also affect the methylation process and induce hypermethylation or hypomethylation in gene promoter regions, thereby regulating cellular activities \[[@r20]\].

How do medications such as AEDs function in the epigenome? The DNA methylation pattern is copied by independent enzymatic machinery (*i.e*., DNMTs). DNA methylation occurs immediately after replication by transfer of a methyl moiety from the donor S-adenosyl-l-methionine (SAM) in a reaction catalysed by a DNMT \[[@r13]\]. VPA is a commonly used broad-spectrum antiepileptic drug and an inhibitor of DNMT1, DNMT3a and DNMT3b. This finding also shows that VPA upregulates Reelin protein and glutamic acid decarboxylase 67 (Gad67) mRNA expression by reducing the methylation of their promoters, and dysregulation of these proteins may influence the processes of neuronal migration and positioning in the developing brain \[[@r21]\]. In contrast, the expression of DNMT1 and DNMT3a is elevated in chronically treated ethosuximide-exposed epileptic rats. However, the biological process of this modifying effect is still unclear \[[@r22]\].

In addition to DNMTs, nutrients (*e.g*., folate, homocysteine and vitamin B12) involved in one-carbon metabolism (OCM) can also modify methylation patterns because they can ensure provision of the universal methyl donor SAM for subsequent methylation reactions \[[@r23]\]. A clinical trial showed that VPA or lamotrigine (LTG) monotherapy led to lower serum folate levels in epilepsy patients. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in OCM because it reduces N5,10-methylenetetrahydrofolate to methyltetrahydrofolate, which can affect the DNA methylation process. In addition, methylation status of the MTHFR amplicon was shown to correlate with serum folate levels, indicating that AEDs may have an effect on methylation by reducing folate levels \[[@r24]\]. Another study showed that VPA-treated patients had both higher serum homocysteine and vitamin B12 levels, which can both affect the OCM \[[@r25]\].

The first-generation AED phenobarbital (PB) is associated with a variety of epigenetic alterations. In a toxicological experiment, PB served as a chemical to investigate the relationship between the apical and epigenetic endpoints. Specific endpoints, such as the transposable element long interspersed element 1 (LINE-1), were found to be hypomethylated in the hepatocytes of rats after exposure to PB. The expression of three genes involved in DNA methylation, DNMT1, DNMT3b and methyl-CpG-binding domain 1 (MBD1), showed a dose-dependent decreasing trend in expression after treatment with PB \[[@r26]\]. Although methyl-binding proteins such as MBD1 do not directly interfere with the methylation process of DNA, they can bind to methylated gene loci and repress their expression \[[@r27]\].

Cannabidiol (CBD), which is used to treat Dravet syndrome, has also been found to increase the expression of DNMT1 to control global DNA methylation levels \[[@r28]\].

2.2. Histone Modification {#sec2.2}
-------------------------

Histone modifications manipulate transcription and other DNA template functions. This process is regulated by specific enzymatic mechanisms that entail metabolites to serve as cosubstrates or act as activators/inhibitors. One of the most common modes of histone modification is acetylation. Histone acetylation neutralizes positively charged lysine residues, which are highly abundant in histone proteins, thereby "opening up" chromatin and making the DNA more accessible to other protein factors \[[@r29]\]. The acetylation status of histones is regulated by a balance between the activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Mammalian HDACs are divided into 4 classes based on their homology to yeast orthologues and their cofactor dependence (class I, IIa, IIb, III, and IV) \[[@r30]\].

An inhibition in HDACs causes the accumulation of acetylated forms of proteins, thus regulating gene expression, cell proliferation and cell death. HDAC inhibition has the potential to treat diverse diseases, especially in anticancer areas \[[@r11]\]. Many AEDs can act as HDAC inhibitors (HDACIs) and play a critical role in the plurality of gene expression mechanisms. VPA is the first known AED that exhibits nonselective inhibition of HDACs \[[@r31]\]. Carbamazepine (CBZ) and topiramate (TPM) were later discovered to also be HDACIs \[[@r12], [@r32]\]. In a recent study, HDAC levels were decreased in rodent brain tissues after treatment with lacosamide (LCM), which supports that the effect of LCM can suppress HDAC activity and enhance the cognitive function of experimental animals \[[@r33]\]. Although levetiracetam (LEV) cannot directly affect HDAC activity, 2-pyrrolidinone-n-butyric acid (PBA), the main metabolite of LEV, promotes histone deacetylation in HeLa cells \[[@r34]\].

2.3. Untranslated RNA {#sec2.3}
---------------------

Untranslated RNA is also a critical component of epigenetic modifications. Although these RNAs lack the potential to encode proteins, they can impinge on the expression of other genes through a variety of mechanisms \[[@r35]\]. miRNAs form a major class of functional, noncoding RNAs. Accumulating evidence has demonstrated miRNA changes in animal models or patients with different conditions, which reveals the potential for miRNAs to serve as novel biomarkers for the diagnosis or treatment of epilepsy, cancer, and other human diseases \[[@r36]-[@r38]\]. AEDs such as VPA can exert anticancer and neuroprotective actions by regulating miRNA levels \[[@r39], [@r40]\].

However, aberrant miRNA expression may lead to abnormal protein expression, and these unintended reactions can be mediated by AEDs. For example, prenatal exposure to VPA causes an immediate augmentation of miR-132 levels in the mouse embryonic brain and then decreases its molecular targets, methyl-CpG-binding protein 2 (MECP2) and Rho GTPase-activating protein (p250GAP), which may result in autism-like behaviour and pathological changes in the mouse cortex \[[@r41]\]. Phenobarbital can cause changes in the expression levels of delta-like homologue 1 gene and type III iodothyronine deiodinase gene (Dlk1-Dio3). These genes are capable of expressing non-coding RNA clusters. And fluctuations in these RNAs can be associated with hepatocyte hypertrophy and recoding and eventually induce liver cancer \[[@r42]\]. Additional experiments support the robust linkage between miRNA changes induced by PB and liver cancer in rodent models \[[@r26]\]. Similarly, cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS), caused by CBZ are believed to be related to the dysregulation of miRNAs in an immune cell experimental analysis \[[@r43]\]. This finding will be restated in subsequent chapters.

Encouragingly, recent experimental studies and reviews have shed light on the use of synthetic miRNA mimics or antagonists to slow the progression of chronic diseases, such as cancer, epilepsy and metabolic diseases, in animal models and clinical trials \[[@r35], [@r37], [@r44], [@r45]\] However, disadvantages such as off-target effects and poor cellular uptake still challenge the practical transformation that must be addressed. Unlike lipophilic drugs, antimiRNAs cannot move into cells by passive diffusion; size and polarity impede their ability to diffuse across lipid bilayers. For example, doxorubicin is smaller than 600 Daltons, while full-length antimiRNAs are ten times bigger than them in size. Due to miRNA structure and function, miRNAs may not work in combination with proteins. Even though miRNAs enter cells, they may combine with other proteins or nucleic acids, resulting in off-target effects \[[@r46]\]. In other words, these findings indicate that miRNA-based therapeutic strategies will have a promising future if such problems are resolved.

3. APPLICATION OF THE EPIGENETIC EFFECT OF ANTIEPILEPTIC DRUGS {#sec3}
==============================================================

As depicted in Fig. **[1](#F1){ref-type="fig"}**, the importance of epigenetics throughout the pathogenesis and treatment of various diseases suggests that AEDs may be used to exert epigenetic effects in various diseases and research fields other than epilepsy, such as tumours, cardiovascular diseases, stem cell research, kidney disease, ADRs and toxicity. Their application in disease and stem cell research can be seen in Table **[1](#T1){ref-type="table"}**. ADRs and toxicity are shown in Table **[2](#T2){ref-type="table"}**.

3.1. The Treatment and Diagnosis of Different Diseases {#sec3.1}
------------------------------------------------------

### 3.1.1. Epilepsy {#sec3.1.1}

Epilepsy is a clinically common neurologic condition, which over 50 million people worldwide at present are believed to experience \[[@r47]\]. Pharmacotherapy is an essential part of controlling seizures, but nearly 30% of patients develop drug-resistant epilepsy \[[@r48]\]. Hence, the search for biomarkers of epilepsy has become a novel focus of studies on the treatment and diagnosis of this disease \[[@r49]\].

This issue raises a question as to whether the epigenetic effects of AEDs are related to their antiseizure effects or the formation of drug resistance. Mathew *et al*. indicated that promoter variants and epigenetic factors determine the transcriptional overexposure of drug targets and may contribute to pharmacoresistance to LEV \[[@r50]\]. Multidrug resistance protein 1 (MDR1), a kind of efflux transporter involved in the occurrence of drug-resistant epilepsy, is overexpressed with exposure to HDACIs, including VPA. Transporter upregulation is associated with histone acetylation, as shown by increased levels of acetylated histone H3 \[[@r51]\].

Epigenetics may explain the mechanism of action of AEDs. A previous study demonstrated that the expression of the sodium channel SCN3A can enhance the excitability of neurons and aggravate the condition of epilepsy, while VPA can downregulate the expression of SCN3A *in vitro*. Results surprisingly show that VPA increases the methylation of the -39C site in the SCN3A promoter. Furthermore, VPA can upregulate fat mass and obesity-associated (FTO) protein, which may repress the expression of MBD2 and NaV1.3. This finding provides a new explanation for the mechanism of VPA exerting its anticonvulsant action \[[@r52]\]. Dezsi *et al.* discovered ethosuximide antiepileptogenic effects in the genetic absence rat model of genetic generalized epilepsy, which is related to its increased expression of DNMT mRNA in the cortex \[[@r22]\].

miRNAs such as miR-134, miR-181a, miR-124, miR-199a, miR-128, miR-15a-5p and miR-194-5p play important roles as diagnostic and therapeutic biomarkers in patients with epilepsy \[[@r53]\]. In addition, preclinical data have described miRNA therapy and its curative effects in animal models \[[@r44]\]. Therefore, we can see that a novel trend in epigenetic therapy has been used in preclinical experiments of epilepsy. Will the next AED be an epigenetic modifier? Based on the latest report on AED development, adenosine kinase (ADK) inhibitors and adenosine should be investigated because of their demethylation function in obstructing the SAM-dependent transmethylation pathway \[[@r54]\].

### 3.1.2. Tumours {#sec3.1.2}

Epigenetic alterations allow a tumour cell to adapt to changes in its microenvironment, and these changes are reversible. Hence, some dormant, hypermethylated tumour suppressor genes can be awakened with drugs \[[@r3]\]. In addition, HDACIs can induce differentiation, cell cycle arrest, and apoptosis *in vitro* \[[@r55]\], which makes it possible to apply demethylating agents and HDACIs in the treatment of patients with cancer.

VPA is a powerful HDACI with the potential to serve as an effective drug for cancer therapy due to its functional induction of cell differentiation \[[@r31]\]. A recent study also emphasized the direct suppression of cancer proliferation by an HDACI to glioblastoma, small cell lung cancer and breast cancer \[[@r56]-[@r58]\]. Interestingly, HDACIs may also promote the growth of cancer cells. La Noce *et al.* suggested that VPA induces an expansion of osteosarcoma, while decreasing expression of HDAC2 is a key factor regulating both phenotype and cancer cell growth *in vivo* \[[@r59]\].

Another antitumour mechanism is that VPA enhances the sensitivity to chemotherapy drugs or radiotherapy. For example, VPA can enhance the efficacy of fluoropyrimidine-based chemical radiotherapy in colorectal cancer by increasing the expression of p53. The p53 gene is the critical factor that causes the resistance of cancer cells \[[@r60]\]. In addition, VPA augments paclitaxel-mediated photodynamic therapy in colorectal cancer, overcoming resistance to paclitaxel and reactivating the expression of CDKN1A epigenetically \[[@r61]\]. Evidence demonstrates that tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-VPA combination therapy can induce the apoptosis of papillary thyroid cancer (PTC) cells by activating caspases. The apoptosis of drug-resistant PTC cells mediated by VPA can be explained by its participation in the regulation of Nrf2 and Bcl-xL expression, indicating the potential for VPA in combination chemotherapy for the treatment of drug-resistant PTC \[[@r62]\]. In a previous experiment, VPA significantly hindered the growth of temsirolimus-resistant prostate cancer cells *in vitro*. An evaluation of the histone acetylation status revealed increased aH3 and aH4 expression in the resistant and sensitive cells, suggesting an epigenetic mechanism \[[@r63]\]. Recent investigations have shown that VPA also promotes cisplatin sensitivity \[[@r64]\] and restores erlotinib \[[@r65]\], sorafenib \[[@r66]\], gemcitabine, and vincristine responsiveness \[[@r67], [@r68]\]. However, the specific molecular mechanisms need to be verified in future research.

A retrospective cohort study suggested that LEV may have a survival advantage in patients with glioblastoma who receive temozolomide (TMZ) chemotherapy \[[@r69]\]. Scicchitano *et al*., found that LEV reduces the expression of O6-methylguanine-DNA methyltransferase (MGMT), which promotes the nuclear translocation of the HDAC4 gene, activates the apoptotic pathway and enhances the effect of temozolomide (TMZ) on the proliferation of glioblastoma multiforme (GBM) cells, indicating that TMZ combined with LEV may improve TMZ clinical efficacy in GBM \[[@r70]\].

miRNA regulation also plays a significant role in the epigenetic therapy of cancer. Manifold pathways involved in tumour initiation, progression and metastasis will malfunction if certain miRNAs are altered \[[@r37]\]. Rizzo *et al*. discovered that brivaracetam and lacosamide regulate the expression of miRNAs in glioma cells; in particular, the regulation of miR-195-5p seems to affect the cell cycle, while the regulation of miR-107 seems to be involved in the inhibition of cell migration; therefore, these two drugs also have the potential to be an adjuvant treatment for glioma \[[@r71]\]. A recent study demonstrated that the VPA-induced simultaneous downregulation of EGFR, ErbB2, and ErbB3 in pancreatic cancer cells could slow the progression of pancreatic cancer, which was mainly attributed to the induction of ErbB family member-targeting miRNAs \[[@r40]\]. Moreover, recent evidence has shown that miR-145-5p upregulation in thymoma cells mediated by VPA exhibits antitumour effects as well as better responsiveness to chemotherapy \[[@r72]\].

### 3.1.3. Psychological Disorders and Neuroprotective Function {#sec3.1.3}

Genetic mechanisms may explicate underlying factors of psychological disorders such as depression and schizophrenia. The epigenetic consequences of early conditions can be eliminated using pharmacological interventions, which give great hope to the treatment of psychiatric disorders \[[@r8]\].

AEDs have psychotropic potential. Their pharmacological actions are multiple, and their genetic regulatory functions, especially epigenetic modifications, play an important role in these functions \[[@r73], [@r74]\]. BRD1 is a susceptibility gene for schizophrenia and bipolar disorder \[[@r75]\]. VPA or CBZ exposure can induce the transcriptional upregulation of BRD1 *in vitro* by demethylating the BRD1 promoter, but CBZ has no such effect on demethylation. This finding indicates that BRD1 can be a potential drug target in schizophrenia \[[@r76]\]. Drugs that show the potential for the treatment of schizophrenia through epigenetic effects include oxcarbazepine (OXC) \[[@r77]\] and CBD \[[@r78]\], which act as an HDACI and DNA demethylating agent, respectively. However, the role of OXC seems to be less effective than that of other potent HDACIs such as VPA and 5-azacytidine. Preclinical experiments have shown that VPA, CBZ, LEV, and LTG can inhibit HDAC2/3/5 in different brain regions, which sheds light on the relationship between antidepressant-like effects and HDACIs \[[@r79]\]. One mechanism reported recently is that VPA upregulates the melatonin receptor MT1, which may have an antidepressive effect \[[@r80]\]. Another common psychological disorder, bipolar disorder, may be related to the epigenetic effects of VPA. VPA treatment influences DNA methylation patterns over and above cell type composition in patients with bipolar disorder, indicating the biological mechanisms underlying drug efficacy \[[@r81]\].

Epigenetic modifications are also involved in basic aspects of brain function in addition to their association with psychiatry. They are commonly reflected in neuroprotective function in drug administration. A preclinical experiment indicated that a decrease in HDAC1 levels in rat and mouse brain tissues treated with lacosamide enhanced cognitive function and exerted a potential neuroprotective effect in Alzheimer\'s disease \[[@r33]\]. VPA can reduce traumatic neural injuries *in vivo* and *in vitro* as an HDACI, and specific isoforms of HDAC serve as possible targets of the molecular mechanism \[[@r82]\]. In addition, an augmentation in epigenetic regulatory factors such as FGF21 and BDNF may also be a mechanism by which VPA exerts its robust neuroprotective function \[[@r39], [@r83]\]. da Silva VK *et al*'s research found that CBD can reduce the methylation of mitochondrial DNA, thereby reducing the loss of mitochondrial ferritin in rats. This protein loss is thought to be associated with some neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's diseases \[[@r84]\]. In Parkinson's disease, the key pathogenic factor is the lack of dopamine. Green and colleagues discovered that VPA can upregulate the expression of dopamine transporters, thereby increasing the content of dopamine. This effect may elucidate VPA's neuroprotective potentialities in models of Parkinson's disease \[[@r85]\]. However, since VPA also causes reversible Parkinson\'s symptoms in clinical applications \[[@r86]\], its efficacy needs to be further evaluated in an *in vivo* model.

### 3.1.4. Cardiovascular Disease, Diabetes and Renal Disease {#sec3.1.4}

In the cardiovascular system, HDACs control processes such as hypertrophy, fibrosis, apoptosis, and energy metabolism. Accumulating evidence has shown their remedial effect in the heart in preclinical models \[[@r87], [@r88]\]. The HDAC9 gene is thought to be associated with atherosclerosis in preclinical data \[[@r89]\]. An analysis of prospective cohort studies showed that VPA reduces the risk of recurrent ischaemic stroke in patients with a previous stroke or transient ischaemic attack, suggesting that exposure to VPA, an inhibitor of HDAC, may be associated with a lower recurrent stroke risk \[[@r90]\]. The efficacy of VPA for the prevention of recurrent ischaemic stroke is worth further clinical assessment. In a mouse model, Choi *et al*. found that VPA prevented hypertension caused by a high-fat diet by inhibiting HDAC1 and downregulating the expression of angiotensin II and its receptor, which implies a new treatment option for hypertension \[[@r91]\]. A recent study showed that another gene, HDAC2, is related to cardiac fibrosis and apoptosis in muscle cells. VPA can act as an inhibitor to restrain the dysregulation of specific pathways, such as oxidative phosphorylation or RhoA signalling, suggesting that VPA has the potential to delay arterial remodelling and the onset of atrial fibrillation in patients at risk \[[@r92]\].

The application of VPA as an HDACI extends to other disease areas. For example, recent studies have found that VPA inhibits HDAC in different isoforms as an antidote for attenuating renal fibrosis and type 2 diabetes \[[@r93], [@r94]\].

3.2. Stem Cell Research {#sec3.2}
-----------------------

Epigenetic reprogramming occurs in primordial germ cells and in the early embryo. DNA methylation of a few crucial loci is required to restrict their differentiation potential \[[@r95]\]. However, these inheritable changes are reversible when epigenetic modifiers are present.

The antiepileptic drug VPA has the powerful ability to induce neural differentiation and neural axis growth in pluripotent stem cells \[[@r96]\]. However, the underlying mechanisms are unknown. Based on this finding, Zhang *et al*. found that VPA activated the mTOR signalling pathway, increased mTOR activity, and demethylated the Ngn1 promoter region, which significantly enhanced the differentiation of rat and neural stem cells \[[@r97]\].

The method of inducing stem cell differentiation and proliferation is also applied to the study of various preclinical stem cell therapies. For instance, VPA treatment decreases the neural progenitor markers Nestin, Notch2 and Sox and improves the differentiation of sympathoadrenal progenitor cells into catecholaminergic neurons with significantly elevated levels of epinephrine. The induction of chromaffin progenitors may be used in the transplantation therapies of neurodegenerative diseases \[[@r98]\]. Another study showed that HDACIs such as VPA may represent a simple and straightforward strategy for the expansion of phenotypic mouse tendon stem cells and retain the function for tendon repair \[[@r99]\].

3.3. ADRs and Toxicity {#sec3.3}
----------------------

### 3.3.1. Carcinogenicity {#sec3.3.1}

Although some drugs have been determined to be nontoxic in traditional toxicity tests, they are reported to have a certain "biological effect". Therefore, some researchers believe that it is necessary to consider a new concept of toxicity, namely, "epigenetic toxicity" \[[@r103], [@r104]\]. Chemical compounds are anticipated to be able to be classified as epigenetic carcinogens based on mechanistic evidence \[[@r105]\]. Then, we can search for a preventive approach to this carcinogenic effect in the clinic for further analysis of the carcinogenic mechanism.

The International Agency for Research on Cancer classifies PB as a nongenotoxic toxicant, an absolute mammal carcinogen \[[@r106]\]. PB can cause abnormalities in gene expression in hepatocytes; therefore, researchers have also tried to use biomarkers to predict the effect of PB-induced liver cancer in rodent models \[[@r107]\]. Pouche *et al*'s study suggested that the regulation of noncoding RNAs, such as miR-200b and miR-221, can predict the development of liver cancer \[[@r26]\]. The unique mechanism may be that PB alters the expression of specific noncoding RNAs (ncRNAs) by activating CAR. Then, these ncRNAs regulate their target proteins and eventually cause cancer \[[@r42]\].

### 3.3.2. Developmental Neurotoxicity {#sec3.3.2}

AEDs might affect foetal growth. Tomson and Battina summarized different studies suggesting a slightly increased risk of congenital malformations among newborn babies exposed to AEDs during pregnancy \[[@r108]\]. The mechanisms of developmental neurotoxicity mediated by AEDs are also thought to be associated with multiple factors, such as folate metabolism \[[@r109]\] and the expression of placental transporters \[[@r110]\], and epigenetic effects are a non negligible part of this process, which may shed light on possible prevention and treatment strategies of these toxic effects \[[@r111]\]. VPA has the highest risk of teratogenesis among all AEDs \[[@r108]\]. Many studies aim to unravel the link between epigenetic modifications of VPA exposure and the mechanism of teratogenesis. Previous studies have shown that the acetylation and methylation of histones, as well as DNA methylation, in the embryonic neuroepithelium in mice may be related to teratogenic effects \[[@r112]\].

Another neurodevelopmental disorder mediated by AEDs is autism spectrum disorder (ASD). VPA can induce and fabricate an ASD model of rodents, which has been widely used in autism research \[[@r113]\]. In addition to its function in HDAC and DNA methylation, two studies have shown elevated levels of miR-132 and miR-134-5p in brain tissue of the VPA-induced mouse ASD model \[[@r41], [@r114]\]. In summary, these findings suggest that targets for epigenetic biomarkers may contribute to the prevention and treatment of congenital diseases.

Interestingly, in preclinical studies, researchers have also begun to use folic acid, alpha-linoleic acid and other substances to prevent malformations or developmental disorders caused by VPA \[[@r115], [@r116]\]. The epigenetic mechanisms of these therapies should be explored in future studies.

### 3.3.3. Inflammatory Effect {#sec3.3.3}

AEDs can cause inflammatory damage to organs in multiple ways. The liver damage caused by VPA can be explained by epigenetic effects. In a previous study, VPA exposure to human primitive liver cells caused a decrease in the methylation levels of the PPARγ, PPARα, CD36 and AHR genes, thereby inhibiting β-oxidation and increasing fatty acid entry into hepatocytes, possibly explaining the molecular mechanism of VPA-induced hepatic steatosis \[[@r117]\]. VPA-induced cataracts are a rare side effect. Palsamy *et al*. discovered hypomethylated loci of the Keap1 promoter that may lead to the enhanced expression of Keap1. In addition, overexpressed Keap1 decreases the Nrf2 level, thereby abolishing Nrf2-dependent antioxidant protection, which might be responsible for oxidative lenticular proteins and cataracts \[[@r118]\]. In addition, VPA is a cause of pancreatitis. However, unlike oxidative stress, VPA interferes with the proliferation of acinar cells and reprograms embryonic cells through the inhibition of HDAC \[[@r119]\]. Activating inflammatory cells can also cause inflammatory effects. CBZ-induced hypersensitivity reactions, such as SJS, are associated with the activation of CD4^+^ T-cells. A recent study found that miR-18a and miR-155 may be epigenetic factors \[[@r43]\].

### 3.3.4. Drug Metabolism {#sec3.3.4}

An individual's susceptibility to ADRs can be determined by epigenetic effectors, such as pharmaceutical compounds, because of variants in certain genes. The occurrence of an ADR can indicate the epigenetic regulation of metabolic genes \[[@r14]\].

PB and CBZ are both liver enzyme inducers. In a recent study, PB (80 mg/kg)-treated rats had higher expression of Ugt1a6 and Ugt1a7 in brain regions. A marker analysis showed that oxidative stress and histone modifications may promote the transcriptional activation of the Ugt1a6 and Ugt1a7 genes \[[@r120]\]. Ookubo *et al*., suggested that the mechanisms underlying CBZ-induced CYP3A4 expression may be associated with its inhibition of HDAC1 \[[@r79]\].

CONCLUSION
==========

AEDs have contributed to neural stabilization in many ways in epilepsy patients for many years. With the development of epigenetics, there is a growing interest in the functions of AEDs, and they are not limited to the prevention of abnormal discharge. Although this article also mentioned that the toxic effects mediated by AEDs seem to have increased the alertness of researchers, similar epigenetic modifications also have beneficial effects. For example, VPA inhibits the apoptosis of renal tubular epithelial cells by targeting HDAC2 and increasing BMP-7 levels. HDACIs may be potentially effective therapeutic agents for preventing cisplatin nephrotoxicity \[[@r121]\]. However, many drugs lack selectivity for epigenetic targets \[[@r122]\], and AEDs are no exception. These drugs may have both beneficial and harmful effects; for example, valproic acid not only has psychotropic effects (300 mg/kg in mice) \[[@r100]\] but also produces teratogenic effects (400 mg/kg in mice) \[[@r112]\]. The occurrence of negative reactions is often related to factors such as dose, environment, age, sex, and disease of the subject. These negative reactions are a major obstacle to limit the epigenetic role of drugs in clinical applications and require more specific trials to verify drug safety before clinical use.

Another issue to be addressed is that many patients with epilepsy often experience varying degrees of cognitive impairment after receiving antiepileptic drugs \[[@r123]\]. Different antiepileptic drugs may have different effects on cognitive function, among which lamotrigine and levetiracetam are better than first-generation antiepileptic drugs such as VPA, PHT and PB in the cognitive recovery of epilepsy patients \[[@r124]\]. Therefore, what if epigenetic factors could influence this procedure? Additional studies are needed to fill this "gap". However, for these antiepileptic drugs in various fields of research, the answer will eventually be revealed.

In summary, there are plentiful preclinical data that have been obtained in recent years that may provide implications for future clinical studies aiming to elucidate the potential preventive and therapeutic role(s) of AEDs in human medicine.

The authors sincerely thank the medical staff of the Huashan Hospitals of Shanghai, China, for their help.
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![**Mechanisms of epigenetic effects mediated by AEDs and how their epigenetic effect applies to diverse research fields.** AEDs affect DNA methylation and histone modification by intervening with enzymes such as DNMTs, HDACs, methyl-binding proteins, such as MBD1, and the methyl donor SAM. They also affect the expression levels of noncoding RNAs. DNA methylation, histone modification, and noncoding RNA regulation can act as epigenetic factors that subsequently influence the expression of target genes. Expression products, such as proteins, peptides and noncoding RNAs, exert biomarker-based predictive, preventive, diagnostic and therapeutic functions in miscellaneous diseases, stem cell research, adverse drug reactions and toxicity.](CN-18-153_F1){#F1}

###### Epigenetic-based functions of AEDs associated with disease and stem cell research.

  **Drug**                                **Gene**                         **Molecular Effect**                   **Functional Effect**                 **Species**   **Refs.**
  --------------------------------------- -------------------------------- -------------------------------------- ------------------------------------- ------------- ------------
  VPA                                     P53                              Histone acetylation                    Antitumour effect                     Human         \[[@r60]\]
  M65, M30                                H3 acetylation                   Antitumour effect                      Human                                 \[[@r58]\]    
  cdk1, cyclin B, Raptor, others          H3 and H4 acetylation            Antitumour effect                      Human                                 \[[@r63]\]    
  CDKN1A                                  H3 acetylation                   Antitumour effect                      Human                                 \[[@r61]\]    
  cdc25a, cdc2, others                    Histone acetylation              Antitumour effect                      Human                                 \[[@r57]\]    
  MDR1                                    H3 acetylation                   Formation of drug-resistant epilepsy   Human                                 \[[@r51]\]    
  SCN3A                                   DNA methylation                  Treatment of epilepsy                  Mouse                                 \[[@r52]\]    
  BRD1                                    DNA methylation                  Biomarker of psychological disorder    Human                                 \[[@r76]\]    
  RELN, SLC1A2, MTNR1A, others            DNA methylation                  Biomarker of psychological disorder    Human                                 \[[@r81]\]    
  HDAC2/3/5                               H3 acetylation                   Biomarker of psychological disorder    Mouse                                 \[[@r79]\]    
  Ube3a                                   H3 and H4 acetylation            Psychotropic effect                    Mouse                                 \[[@r100]\]   
  MT1                                     H3 acetylation                   Psychotropic effect                    Rat                                   \[[@r80]\]    
  STAT1, p65                              Histone acetylation              Neuroprotective function               Rat                                   \[[@r101]\]   
  HIF1a, HSP70, p-mTOR, Tubulin           Histone acetylation              Neuroprotective function               Mouse, Swine                          \[[@r82]\]    
  Pitx3, Nurr1                            H3 acetylation                   Neuroprotective function               Rat                                   \[[@r85]\]    
  FGF21                                   H3 acetylation                   Neuroprotective function               Rat                                   \[[@r83]\]    
  Ang II                                  H3 and H4 acetylation            Treatment of hypertension              Mouse                                 \[[@r91]\]    
  CREM                                    H4 acetylation                   Treatment of atrial fibrillation       Mouse                                 \[[@r92]\]    
  FoxO1                                   Histone acetylation              Treatment of type 2 diabetes           Rat                                   \[[@r93]\]    
  ECM                                     H3 acetylation                   Treatment of renal disease             Mouse                                 \[[@r94]\]    
  CD133, OCT4, SOX2, NANOG, others        DNA methylation,H3 acetylation   Cell proliferation                     Human                                 \[[@r59]\]    
  Scx                                     H3 acetylation                   Cell proliferation                     Mouse                                 \[[@r99]\]    
  Nestin, Notch2, Sox10, others           H3 acetylation                   Cell differentiation                   Bovine                                \[[@r98]\]    
  miR-122-5p                              Upregulation                     Cell differentiation                   Human                                 \[[@r102]\]   
  Ngn1                                    DNA methylation                  Cell differentiation                   Rat                                   \[[@r97]\]    
  miR-145-5p                              Upregulation                     Antitumour effect                      Human                                 \[[@r72]\]    
  miR-125a, miR-125b, miR-205, miR-133b   Upregulation                     Antitumour effect                      Mouse                                 \[[@r40]\]    
  miR-124                                 Upregulation                     Neuroprotective function               Mouse                                 \[[@r39]\]    
  CBZ                                     BRD1                             DNA methylation                        Biomarker of psychological disorder   Human         \[[@r76]\]
  HDAC2/3/5                               H3 acetylation                   Biomarker of psychological disorder    Mouse                                 \[[@r79]\]    
  LEV                                     MGMT                             Histone acetylation                    Antitumour effect                     Human         \[[@r70]\]
  HDAC2/3/5                               H3 acetylation                   Biomarker of psychological disorder    Human                                 \[[@r79]\]    
  LCM                                     HDAC1                            Histone acetylation                    Neuroprotective function              Rat           \[[@r33]\]
  miR-195-5p                              Upregulation                     Antitumour effect                      Human                                 \[[@r71]\]    
  miR-107                                 Downregulation                   Antitumour effect                      Human                                 \[[@r71]\]    
  CBD                                     CB1                              DNA methylation                        Psychotropic effect                   Rat           \[[@r78]\]
  mitochondrial ferritin                  DNA methylation                  Neuroprotective function               Rat                                   \[[@r84]\]    
  BRV                                     miR-195-5p                       Upregulation                           Antitumour effect                     Human         \[[@r71]\]
  miR-107                                 Downregulation                   Antitumour effect                      Human                                 \[[@r71]\]    
  OXC                                     GABRB2                           DNA methylation                        Psychotropic effect                   Human         \[[@r77]\]
  LTG                                     HDAC2/3/5                        H3 acetylation                         Biomarker of psychological disorder   Mouse         \[[@r79]\]
  ESX                                     DNMT1, DNMT3a                    DNA methylation                        Treatment of epilepsy                 Rat           \[[@r22]\]

Representative examples of studies and epigenetic effects are summarized. VPA valproate acid, CBZ carbamazepine, LEV levetiracetam, LCM lacosamide, ESX ethosuximide, LTG lamotrigine, BRV brivaracetam, OXC oxcarbazepine, CBD cannabidiol.

###### Epigenetic-based application of AEDs associated with adverse drug reactions and toxicity.

  **Drug**   **Gene**                   **Molecular Effect**             **ADR or Toxicity**            **Species**   **Refs.**
  ---------- -------------------------- -------------------------------- ------------------------------ ------------- -------------
  VPA        BMP-7                      Histone acetylation              Antitoxic effect               Mouse         \[[@r121]\]
             PPARγ, PPARα, AHR, CD36    DNA methylation                  Induces hepatocyte steatosis   Human         \[[@r117]\]
             Keap1                      DNA methylation                  Induces cataracts              Human         \[[@r118]\]
             MTHFR                      DNA methylation                  Affects folate metabolism      Human         \[[@r25]\]
             Sox9                       H3 acetylation                   Induces pancreatitis           Mouse         \[[@r119]\]
             miR-134-5p                 Upregulation                     Induces autism                 Rat           \[[@r114]\]
             miR-132                    Upregulation                     Induces autism                 Mouse         \[[@r41]\]
  PB         LINE-1                     DNA methylation                  Carcinogenesis                 Rat           \[[@r26]\]
             Ugt1a6, Ugt1a7             H3 acetylation, H3 methylation   Affects drug metabolism        Rat           \[[@r120]\]
             Dlk1-Dio3, IncRNAs         Upregulation                     Carcinogenesis                 Mouse         \[[@r42]\]
             miR-200b                   Upregulation                     Carcinogenesis                 Rat           \[[@r26]\]
             miR-221                    Downregulation                   Carcinogenesis                 Rat           \[[@r26]\]
  CBZ        CYP3A4                     Histone acetylation              Affects drug metabolism        Human         \[[@r79]\]
             miR-155, miR-18a, miR-21   Upregulation                     Induces a cutaneous reaction   Human         \[[@r43]\]
  LTG        MTHFR                      DNA methylation                  Affects folate metabolism      Human         \[[@r25]\]

Representative examples of studies and epigenetic effects are summarized. ADRs adverse drug reactions, VPA valproic acid, CBZ carbamazepine, LEV levetiracetam, LCM lacosamide, PB phenobarbital, LTG lamotrigine.
